Salvage therapy for relapsed and refractory Hodgkin lymphoma Book Section
| Authors: | Yahalom, J.; Rimner, A.; Tsang, R. W. |
| Editors: | Specht, L.; Yahalom, J. |
| Article/Chapter Title: | Salvage therapy for relapsed and refractory Hodgkin lymphoma |
| Abstract: | Patients with Hodgkin lymphoma (HL) who remain refractory to their chemotherapy-based primary treatment or relapse after obtaining a remission still have a very good chance of cure with appropriate salvage therapy. Most will be good candidates for high-dose therapy (HDT) programs that are supported with infusion of their autologous peripheral blood stem cells. Most programs start with standard-dose chemotherapy for response re-induction in an attempt to maximize tumor reduction prior to HDT. In special circumstances, other salvage options with standard-dose chemotherapy and/or radiation therapy (RT) are available and are also discussed below. Radiation therapy should play a major role in the salvage effort of chemotherapy or combined-modality failures, as often its benefits have not been exploited with the primary treatment. Methods of integrating RT effectively and safely into the salvage effort are discussed in this chapter. © 2011 Springer-Verlag Berlin Heidelberg. |
| Book Title: | Radiotherapy for Hodgkin Lymphoma |
| ISBN: | 978-3-540-78455-5 |
| Publisher: | Springer Berlin Heidelberg |
| Publication Place: | Heidelberg, Germany |
| Date Published: | 2011-01-01 |
| Start Page: | 31 |
| End Page: | 44 |
| Language: | English |
| DOI: | 10.1007/978-3-540-78944-4_4 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 4 -- 9783540784555 (ISBN) -- Export Date: 3 March 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work